Brief: Pulmatrix Announces First Subject Dosed In Phase 1 Study Of Pur3100 For Acute Migraine
12/07/2022 14:41
July 12 (Reuters) - Pulmatrix Inc PULM.O :
* PULMATRIX ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 STUDY
OF
PUR3100 FOR ACUTE MIGRAINE
Source text for Eikon: ID:nPn3DYLhCa
Further company coverage: PULM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Pulmatrix
See all newsBrief: Pulmatrix Announces Second Quarter 2026 Financial Results And Progress On Merger
Pulmatrix Q2 loss narrows on clinical development hold
Pulmatrix Q1 net loss narrows, clinical development on hold
Brief: Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger
NASDAQ RESUMED AT 09:00 AM